Novartis Stockpiling Priority Review Vouchers
Firm picks up second PRV with purchase from Ultragenyx, which is expected to use the $130m to help advance its rare disease development pipeline.
You may also be interested in...
Novartis’ Attention To Tropical Diseases Pays Off: Liver Fluke Drug Egaten Earns Priority Review Voucher
US FDA approval expected to facilitate global use of one-day oral treatment of fascioliasis, a designated neglected tropical disease, which Novartis developed with the World Health Organization.
The latest drug development news and highlights from our US FDA Performance Tracker.
BioMarin's sale of voucher earned with approval of rare pediatric disease drug Brineura the fourth publicly disclosed voucher sale this year with a price tag between $125m and $150m.